Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Co. is engaged in the discovery, research and development activities around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Co. discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform. Co.'s commercial product, plecanatide, under trademark name TRULANCE is for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The SGYP average annual return 10 years is shown above.
The Average Annual Return on the SGYP average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SGYP average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SGYP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|